


Improvement of HCV screening and linkage to care through implementation science in Madeira, Portugal

Vítor Magno Pereira¹, Elisa Xavier¹, Luís Jasmins¹, Ana Paula Reis¹, Nancy Faria¹, Nuno Ladeira¹, Madalena Pestana¹, Bruno Freitas¹, Nuno Canhoto¹, Diogo Medina², Alba Carrodeguas²

¹ Serviço de Saúde da Região Autónoma da Madeira, EPE

² Gilead Sciences

Welcome to Madeira



Welcome to Madeira: The Regional Health Service



254,000

population served



50 units

3 hospitals, 47 health centers







88,000

yearly adult emergency dept. visits



Screening framework: The FOCUS TEST model


-  Testing integrated into routine care
-  Electronically enabled, with automation of eligibility assertion
-  Systematic adoption of screening policy throughout the region
-  Training of staff and monitoring support continuous improvement



TEST: Testing integrated into clinical routine



TEST: Electronic health record modifications



Eligibility criteria

- Age: 18-70 y.o.
- Exclusion factors:
 - Prior positive serologies at any time
 - Prior negative serologies within 365 days
 - Ongoing serology in lab



TEST: Systemic adoption of policies

 Secretaria Regional de Saúde e Proteção Civil

SABIA QUE...

Metade das pessoas infetadas com HIV só o descobre em fases muito adiantadas?

A maioria das pessoas infetadas com hepatite B ou C não tem sintomas?

O Serviço de Saúde da RAM faz o rastreio destas doenças, com o objetivo de as diagnosticar e tratar precocemente.

Se tem entre 18 e 70 anos, quando fizer análises de sangue, tem a indicação para os teste de **HIV**, **Hepatite B** e **Hepatite C**.





DIGA SIM AO TESTE.



TEST: Training and engaging staff




Summary of results

	Jan 2022 - May 2023 (17 mo.)
HCV Ab tests performed	35,376
HCV Ab positive tests	171 (0.5% prevalence)
HCV RNA or cAg positive tests	52 (0.15% prevalence)
Linkage to care	49 (94% linked to care)



Progress toward elimination at the regional level

HCV prevalence, three-month moving average, August 2019 to Dec 2022



Conclusions

1. The TEST model enabled Madeira to **increase and sustain testing** across clinical settings (wards, primary care, and the ED)
2. Opportunistic HCV screening revealed **higher real-world prevalence** (0.15% HCV RNA+) than previously estimated for Madeira (0%).
3. Increased testing and decreasing prevalence trends mean Madeira will **likely achieve HCV elimination between 2024 and 2026**, ahead of WHO's elimination goal for 2030.

